Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common stock, par value $0.00001
-
Shares outstanding
-
43,754,363
-
Total 13F shares
-
8,583,076
-
Share change
-
+3,740,989
-
Total reported value
-
$23,775,177
-
Price per share
-
$2.77
-
Number of holders
-
25
-
Value change
-
+$10,367,185
-
Number of buys
-
12
-
Number of sells
-
7
Institutional Holders of Cellectar Biosciences, Inc. - Common stock, par value $0.00001 (CLRB) as of Q4 2023
As of 31 Dec 2023,
Cellectar Biosciences, Inc. - Common stock, par value $0.00001 (CLRB) was held by
25 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,583,076 shares.
The largest 10 holders included
Rosalind Advisors, Inc., AIGH Capital Management LLC, ADAR1 Capital Management, LLC, Nantahala Capital Management, LLC, Worth Venture Partners, LLC, VANGUARD GROUP INC, ACUTA CAPITAL PARTNERS, LLC, CITADEL ADVISORS LLC, GEODE CAPITAL MANAGEMENT, LLC, and BlackRock Inc..
This page lists
25
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.